1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 16,200 | 18,300 | 30.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 24.03. | Sartorius Stedim Biotech SA: Resolutions of the Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. | 371 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): AGM/EGM
Resolutions of the Combined Annual Shareholders' Meeting of Sartorius Stedim Biotech S.A. 24-March-2026 / 15:32 CET/CEST
Aubagne... ► Artikel lesen | |
| 17.03. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets | 558 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Forecast
Sartorius Stedim Biotech sharpens strategy with biopharma focus and sets new mid-term growth targets 17-March-2026 / 07:03... ► Artikel lesen | |
| 02.03. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 417 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 16.02. | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech releases Universal Registration Document 2025 | 557 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): Annual Results
Sartorius Stedim Biotech releases Universal Registration Document 2025 16-Feb-2026 / 09:13 CET/CEST
Aubagne, France... ► Artikel lesen | |
| 06.02. | Board of Directors of Sartorius Stedim Biotech S.A. resolves dividend proposal of 0.69 euros | 434 | Dow Jones News | DJ Board of Directors of Sartorius Stedim Biotech S.A. resolves dividend proposal of 0.69 euros
Sartorius Stedim Biotech SA / Key word(s): Dividend
Board of Directors of Sartorius Stedim Biotech... ► Artikel lesen | |
| 03.02. | Sartorius Stedim Biotech FY25 Results Climb; Sees Growth In FY26, Beyond | 472 | AFX News | PARIS (dpa-AFX) - Sartorius Stedim Biotech S.A. (SRTOY, SDMHF, DIM.PA) reported Tuesday higher profit and sales revenues in fiscal 2025, with growth in all regions. Looking ahead for fiscal... ► Artikel lesen | |
| SARTORIUS STEDIM BIOTECH SA ADR Aktie jetzt für 0€ handeln | |||||
| 03.02. | Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook | 819 | Dow Jones News | DJ Sartorius Stedim Biotech achieves considerable profitable growth in 2025 and maintains positive outlook
Sartorius Stedim Biotech SA / Key word(s): Preliminary Results
Sartorius Stedim Biotech... ► Artikel lesen | |
| 03.02. | Sartorius Stedim Biotech S.A. Non-GAAP EPS of €4.40, revenue of €2.97B; initates FY26 outlook | 4 | Seeking Alpha | ||
| 02.02. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 374 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 12.01. | Goldman Sachs stuft Sartorius Stedim Biotech nach Kursrallye herab | 5 | Investing.com Deutsch | ||
| 12.01. | Goldman Sachs downgrades Sartorius Stedim Biotech stock rating after recent rally | 3 | Investing.com | ||
| 06.01. | Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech | 878 | Dow Jones News | DJ Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Half-year liquidity contract statement... ► Artikel lesen | |
| 05.01. | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 502 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 03.12.25 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 521 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 03.11.25 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 563 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen | |
| 16.10.25 | Earnings Call: Sartorius Stedim Biotech steigert Umsatz in Q3 2025 um 7,5 % | 3 | Investing.com Deutsch | ||
| 16.10.25 | Sartorius Stedim Biotech Non-GAAP EPS of €0.94, revenue of €705.7M; raises FY outlook | 3 | Seeking Alpha | ||
| 16.10.25 | Sartorius Stedim Biotech Earnings Up In H1; Lifts FY25 Outlook | 460 | AFX News | PARIS (dpa-AFX) - Sartorius Stedim Biotech S.A. (DIM.PA), a partner to the biopharmaceutical industry, on Thursday reported that net profit increased in the first half of 2025 compared with... ► Artikel lesen | |
| 16.10.25 | Sartorius Stedim Biotech SA: Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025 | 676 | EQS Group (EN) | Sartorius Stedim Biotech SA
/ Key word(s): 9 Month figures
Sartorius Stedim Biotech publishes unaudited results for the first nine months of 2025 16-Oct-2025 / 07:00 CET/CEST
Aubagne... ► Artikel lesen | |
| 06.10.25 | Sartorius Stedim Biotech SA: Declaration Relative to the Number of Shares and Voting Rights Making up the Issued Capital | 561 | Dow Jones News | DJ Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: DECLARATION... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 276,44 | -4,53 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs | ||
| QIAGEN | 34,540 | +1,75 % | QIAGEN N.V.: Qiagen Announces Form 20-F Annual Report Filing for 2025 Results | QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 23,510 | -0,68 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Appoints Jeffrey A. Munsie as Chief Legal Officer | RADNOR, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities... ► Artikel lesen | |
| RELAY THERAPEUTICS | 9,350 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026 | 400mg BID fed is the dose used in the ongoing Phase 3 ReDiscover-2 trial, which initiated mid-2025 11.1-month median PFS in heavily pre-treated patients with PI3Ka-mutated, HR+/HER2- metastatic breast... ► Artikel lesen | |
| BULLFROG AI | 1,070 | 0,00 % | Bullfrog AI stock offers a rare opportunity for investors to take profit | ||
| ALUMIS | 20,130 | 0,00 % | Alumis Inc.: Alumis' Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis | Envudeucitinib achieved robust PASI responses by Week 16, with significant continued improvements by Week 24 in PASI 90 (68.0%, 62.1%) and PASI 100 (41.0%, 39.5%)Quality-of-life improvements and itch... ► Artikel lesen | |
| BIONTECH | 74,25 | -0,07 % | BioNTech SE: BioNTech auf dem ELCC-Kongress 2026: Neue klinische Daten unterstreichen das Potenzial des differenzierten, spätklinischen Portfolios bei Lungenkrebs | Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren... ► Artikel lesen | |
| ADMA BIOLOGICS | 9,165 | 0,00 % | ADMA Biologics, Inc.: ADMA Biologics Issues Statement Refuting Unsubstantiated, Misleading and Inaccurate Allegations by Culper Research | Short seller's Characterization of ASCENIV's Competitive Position Reflects Blatant Misunderstanding of ADMA's Business and Its Role as Late-line Therapy for Patients Who are Immune Compromised and... ► Artikel lesen | |
| ERASCA | 14,940 | 0,00 % | Erasca, Inc.: Erasca Reports Fourth Quarter and Full Year 2025 Business Updates and Financial Results | Encouraging early clinical activity observed during ERAS-0015 dose escalation, including ongoing responses across multiple RAS-mutant tumors with favorable safety, tolerability, and pharmacokinetics... ► Artikel lesen | |
| NUVALENT | 96,81 | +0,16 % | Wells Fargo stuft Nuvalent wegen hohem Medikamentenpotenzial mit "Overweight" ein | ||
| ARCELLX | 114,76 | +0,17 % | Laufende Fusionskontrollverfahren: Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USA | Datum der Anmeldung:13.03.2026Aktenzeichen:B3-41/26Unternehmen:Gilead Sciences, Foster City, CA/USA; Erwerb sämtlicher Anteile an und Kontrolle über die Arcellx, Redwood City, CA/USAProduktmärkte:Hämatologie... ► Artikel lesen | |
| CG ONCOLOGY | 63,90 | -1,19 % | UBS raises CG Oncology stock price target to $90 on trial outlook | ||
| ARRIVENT BIOPHARMA | 21,010 | -1,82 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 36,650 | -5,78 % | Enliven Therapeutics stock price target raised to $56 by H.C. Wainwright | ||
| EVOTEC | 4,270 | -0,81 % | Evotec streicht 800 Stellen - und trotzdem sehen Analysten 100% Kurspotenzial | 800 Stellen weg, Kosten explodiert, Gewinne verschoben - Evotec steckt tief in der Krise. Doch Analysten sehen mehr als 100% Kurspotenzial. Was steckt hinter dem Widerspruch? Rund 800 Stellen werden... ► Artikel lesen |
SARTORIUS STEDIM BIOTECH SA ADR gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 16,100 Euro und damit -1,23 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SARTORIUS STEDIM BIOTECH SA ADR finden Sie auf Wallstreet Online.